Bristol-Myers Squibb Company / Flexus Biosciences, Inc.

Solid tumors (immuno-oncology, IDO1/TDO pathway)

Disease Overview

Indoleamine 2,3-dioxygenase 1 (IDO1) is an immunosuppressive enzyme that catabolizes tryptophan and is upregulated in many solid tumors, creating a tumor microenvironment that suppresses T-cell function and shields cancers from immune attack. IDO1 inhibition was hypothesized to synergize with PD-1/PD-L1 checkpoint inhibitors by removing this immunosuppressive brake. The thesis dominated immuno-oncology dealmaking in 2014-2015 across melanoma, NSCLC, head and neck, and renal cell carcinoma combinations.

Competitive Landscape

At deal announcement (February 2015), the IDO1 inhibitor field was a hotly contested immuno-oncology subspace led by Incyte's epacadostat (partnered broadly with Merck's Keytruda, AstraZeneca's Imfinzi, and BMS's Opdivo), NewLink Genetics' indoximod and navoximod (the latter partnered with Genentech), and a handful of preclinical entrants. BMS bought Flexus to bring in-house a wholly owned IDO1 small molecule (F001287, later BMS-986205) plus a discovery library spanning IDO-selective, dual IDO/TDO, and TDO-selective compounds, reducing reliance on the Incyte partnership. The thesis collapsed in April 2018 when Incyte/Merck's Phase 3 ECHO-301 melanoma trial showed epacadostat+Keytruda offered no progression-free survival benefit over Keytruda alone, triggering broad industry retrenchment. BMS pulled two BMS-986205 Phase 3 trials in NSCLC and head and neck cancer within weeks of the readout. NewLink and others followed suit. The Flexus deal is now widely cited as a cautionary example of biomarker-thin immuno-oncology dealmaking, though IDO1 has shown selective resurgence in newer combinations.